Literature DB >> 15861141

Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Paola Llinas1, Marie Hélène Le Du, Henrik Gårdsvoll, Keld Danø, Michael Ploug, Bernard Gilquin, Enrico A Stura, André Ménez.   

Abstract

We report the crystal structure of a soluble form of human urokinase-type plasminogen activator receptor (uPAR/CD87), which is expressed at the invasive areas of the tumor-stromal microenvironment in many human cancers. The structure was solved at 2.7 A in association with a competitive peptide inhibitor of the urokinase-type plasminogen activator (uPA)-uPAR interaction. uPAR is composed of three consecutive three-finger domains organized in an almost circular manner, which generates both a deep internal cavity where the peptide binds in a helical conformation, and a large external surface. This knowledge combined with the discovery of a convergent binding motif shared by the antagonist peptide and uPA allowed us to build a model of the human uPA-uPAR complex. This model reveals that the receptor-binding module of uPA engages the uPAR central cavity, thus leaving the external receptor surface accessible for other protein interactions (vitronectin and integrins). By this unique structural assembly, uPAR can orchestrate the fine interplay with the partners that are required to guide uPA-focalized proteolysis on the cell surface and control cell adhesion and migration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15861141      PMCID: PMC1142576          DOI: 10.1038/sj.emboj.7600635

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  54 in total

1.  Modeling the structure of agitoxin in complex with the Shaker K+ channel: a computational approach based on experimental distance restraints extracted from thermodynamic mutant cycles.

Authors:  Mats A L Eriksson; Benoît Roux
Journal:  Biophys J       Date:  2002-11       Impact factor: 4.033

2.  Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.

Authors:  Henrik Gårdsvoll; Finn Werner; Leif Søndergaard; Keld Danø; Michael Ploug
Journal:  Protein Expr Purif       Date:  2004-04       Impact factor: 1.650

3.  High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.

Authors:  R J Goodson; M V Doyle; S E Kaufman; S Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

4.  Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.

Authors:  H M Zhou; A Nichols; P Meda; J D Vassalli
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

5.  Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.

Authors:  L H Engelholm; N Behrendt
Journal:  Biol Chem       Date:  2001-03       Impact factor: 3.915

6.  Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.

Authors:  M Ploug; S Ostergaard; L B Hansen; A Holm; K Danø
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162

7.  Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.

Authors:  V Magdolen; P Rettenberger; M Koppitz; L Goretzki; H Kessler; U H Weidle; B König; H Graeff; M Schmitt; O Wilhelm
Journal:  Eur J Biochem       Date:  1996-05-01

8.  Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.

Authors:  Elzbieta Pluskota; Dmitry A Soloviev; Edward F Plow
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

9.  Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.

Authors:  Isabelle Bolon; Hong-Ming Zhou; Yves Charron; Annelise Wohlwend; Jean-Dominique Vassalli
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

10.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Authors:  G Deng; S A Curriden; S Wang; S Rosenberg; D J Loskutoff
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  74 in total

1.  A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.

Authors:  Evelyn C Nieves; Naveen Manchanda
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

2.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

3.  The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia.

Authors:  Henrik Gårdsvoll; Mette C Kriegbaum; Emil P Hertz; Warner Alpízar-Alpízar; Michael Ploug
Journal:  J Histochem Cytochem       Date:  2013-07-29       Impact factor: 2.479

4.  Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.

Authors:  Qing Huai; Aiwu Zhou; Lin Lin; Andrew P Mazar; Graham C Parry; Jennifer Callahan; David E Shaw; Bruce Furie; Barbara C Furie; Mingdong Huang
Journal:  Nat Struct Mol Biol       Date:  2008-03-23       Impact factor: 15.369

5.  D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.

Authors:  Gabriele Eden; Marco Archinti; Ralitsa Arnaudova; Giuseppina Andreotti; Andrea Motta; Federico Furlan; Valentina Citro; Maria Vittoria Cubellis; Bernard Degryse
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

6.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

Review 7.  GPIHBP1, a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins.

Authors:  Anne P Beigneux; Brandon S J Davies; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-10-14       Impact factor: 5.922

8.  Glycosylation of Asn-76 in mouse GPIHBP1 is critical for its appearance on the cell surface and the binding of chylomicrons and lipoprotein lipase.

Authors:  Anne P Beigneux; Peter Gin; Brandon S J Davies; Michael M Weinstein; André Bensadoun; Robert O Ryan; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-03-13       Impact factor: 5.922

9.  Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.

Authors:  A F Lomholt; G Høyer-Hansen; H J Nielsen; I J Christensen
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

10.  Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.

Authors:  Ceri E Stewart; Ian Sayers
Journal:  BMC Mol Biol       Date:  2009-07-28       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.